By the end of this
video you will be able to detail
studies that support the transition of
a molecule into clinical trials including
genetic toxicity, general toxicology, safety pharmacology,
and phototoxicity. Genetic toxicology
testing determines the risk of a molecule
being mutagenic, that is, causing DNA mutations or structural
damage to chromosomes. Molecules that are mutagenic have a risk of causing cancer. A common test for mutagenicity
is the Ames test. The Ames test is performed
on bacteria and is therefore both simple to perform and
provides rapid results. While the Ames test is not a perfect predictor
for carcinogenicity, it is an adequate early
predictor of mutagenicity risk. More extensive studies are
conducted on the molecule if the compound advances into
later clinical trials. General toxicology
studies are another type of testing required before a molecule can be
administered in humans. General toxicology studies
are performed in animals and follow GLP guidelines. Animals included
in these studies include one rodent
species, usually the rat, and one non-rodent, typically dog or
non-human primate, NHP, or monkeys. Studies include repeat dosing of a molecule and groups that
receive a range of doses. Study designs typically include a vehicle control group and low, mid, and high dose level groups of
the experimental drug. Researchers will search for any toxic effects
from the molecule as well as whether
the effects are reversible once
dosing is stopped. If the molecule is known to
target a specific organ, then the health and
function of that organ will receive additional focus
during clinical testing. An additional supporting
pre-clinical test for antibody-based biologics
includes tissue cross-reactivity using the candidate antibody. The potential for a
protein biologics such as an antibody
drug to elicit an immunological response
leading to the formation of anti-drug antibodies
will also be evaluated. Another important
consideration for general toxicology studies is that for every
anticipated day of dosing in a human subject
there must be a day of dosing in an animal
GLP toxicology study. For instance, if
a clinical trial will dose human subjects for 13 weeks there must be a GLP toxicology study of
equivalent or longer duration. This relationship holds until greater than six months
of human dosing, which will be covered
by a six-month study in rodents and a nine-month
study in non-rodents. Oncology studies have slightly different
requirements in that a four-week GLP toxicology
study independent of the duration of
human dosing will cover Phase I and
II clinical trials. Before entering Phase III, a 13-week GLP toxicology
study is required. Safety pharmacology, while it also supports
early clinical studies, is distinct from
general toxicology. Safety pharmacology focuses on acute life-threatening risks of a molecule on key organ systems. Organs and systems of interest include the
cardiovascular system, central nervous system,
and respiratory system. The purpose of safety
pharmacology is to identify uncommon and potentially clinically relevant
adverse events, AEs, that would unlikely be identified by general
toxicology methods. A secondary objective
is to identify a detection method for
the adverse event. The CNS and respiratory
studies are typically performed in rats. Cardiovascular studies
are performed in dogs or non-human primates. Note that cardiovascular
studies include monitoring cardiac QT
prolongation and in vivo assessment of the hERG
or I_Kr activity for which in vitro assays for inhibition of this channel were performed
in earlier discovery stages. Depending upon the
chemical structure of a low molecular
weight compound, there is the potential that
the compound may absorb light in the UV
visible spectrum and under certain circumstances
such as distribution to skin or binding to melanin may
produce phototoxicity. A drug with phototoxic potential may increase the incidence and/or severity of skin
reactions to sunlight exposure. Compounds which have
light-absorbing properties can be tested for phototoxic
potential using an in vitro cell-based
assay that tests for increased cytotoxicity in
the presence of a radiation. An example of a commonly
encountered drug that shows phototoxicity
is the antibiotic, tetracycline, shown in the upper-right
corner of the slide. In vivo pre-clinical studies
on genetic toxicity, general toxicology,
safety pharmacology, and phototoxicity
collectively provide key information on
the safety risk of a molecule so that early
studies in humans can be initiated with minimal
risk to trial participants